BNP Paribas Exane Cuts BWX Technologies (NYSE:BWXT) Price Target to $165.00

BWX Technologies (NYSE:BWXT) had its price target lowered by BNP Paribas Exane from $190.00 to $165.00 in a research note released on Thursday,Benzinga reports. BNP Paribas Exane currently has a neutral rating on the technology company’s stock.

A number of other equities research analysts also recently issued reports on BWXT. Weiss Ratings downgraded BWX Technologies from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, August 26th. Truist Financial reduced their price objective on BWX Technologies from $212.00 to $202.00 and set a “hold” rating on the stock in a research note on Friday, August 14th. BTIG Research reiterated a “buy” rating and set a $235.00 target price on shares of BWX Technologies in a report on Tuesday, August 4th. Jefferies Financial Group started coverage on shares of BWX Technologies in a research report on Thursday, September 3rd. They set a “buy” rating and a $181.00 target price for the company. Finally, Guggenheim initiated coverage on shares of BWX Technologies in a report on Monday, September 14th. They issued a “buy” rating and a $192.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $213.75.

BWX Technologies Stock Down 0.2%

Shares of BWXT opened at $138.37 on Thursday. BWX Technologies has a fifty-two week low of $136.50 and a fifty-two week high of $241.82. The company’s fifty day moving average is $159.93 and its two-hundred day moving average is $188.43. The firm has a market cap of $12.68 billion, a PE ratio of 35.85, a price-to-earnings-growth ratio of 2.17 and a beta of 0.75. The company has a quick ratio of 2.33, a current ratio of 2.40 and a debt-to-equity ratio of 1.51.

BWX Technologies (NYSE:BWXT) last released its quarterly earnings data on Monday, August 3rd. The technology company reported $1.07 EPS for the quarter, topping analysts’ consensus estimates of $1.04 by $0.03. The business had revenue of $901.62 million during the quarter, compared to the consensus estimate of $902.41 million. BWX Technologies had a return on equity of 30.83% and a net margin of 10.11%.The business’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same period in the prior year, the firm posted $1.02 EPS. BWX Technologies has set its FY 2026 guidance at 4.700-4.800 EPS. Analysts forecast that BWX Technologies will post 4.75 earnings per share for the current year.

BWX Technologies Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 4th. Shareholders of record on Tuesday, August 18th were given a $0.27 dividend. The ex-dividend date of this dividend was Tuesday, August 18th. This represents a $1.08 annualized dividend and a yield of 0.8%. BWX Technologies’s dividend payout ratio (DPR) is 27.98%.

Insider Activity at BWX Technologies

In other BWX Technologies news, CEO Rex D. Geveden sold 10,000 shares of the business’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $172.50, for a total transaction of $1,725,000.00. Following the transaction, the chief executive officer owned 192,491 shares in the company, valued at $33,204,697.50. The trade was a 4.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On BWX Technologies

Several hedge funds have recently modified their holdings of the stock. Cannell & Spears LLC boosted its holdings in BWX Technologies by 4.0% in the 1st quarter. Cannell & Spears LLC now owns 1,312 shares of the technology company’s stock worth $251,000 after acquiring an additional 50 shares during the period. Private Advisor Group LLC raised its stake in shares of BWX Technologies by 2.4% during the first quarter. Private Advisor Group LLC now owns 2,847 shares of the technology company’s stock valued at $582,000 after purchasing an additional 67 shares during the period. Moors & Cabot Inc. lifted its position in shares of BWX Technologies by 3.7% during the fourth quarter. Moors & Cabot Inc. now owns 2,040 shares of the technology company’s stock worth $353,000 after purchasing an additional 72 shares in the last quarter. Beck Capital Management LLC lifted its position in shares of BWX Technologies by 0.3% during the fourth quarter. Beck Capital Management LLC now owns 25,032 shares of the technology company’s stock worth $4,327,000 after purchasing an additional 72 shares in the last quarter. Finally, Modera Wealth Management LLC boosted its stake in shares of BWX Technologies by 4.6% in the first quarter. Modera Wealth Management LLC now owns 1,757 shares of the technology company’s stock valued at $359,000 after purchasing an additional 77 shares during the period. 94.39% of the stock is currently owned by hedge funds and other institutional investors.

About BWX Technologies

BWX Technologies, Inc (NYSE: BWXT) is a technology and manufacturing company that specializes in nuclear components, systems and services. The company primarily serves government and commercial customers in the nuclear energy, national security and medical markets.

BWXT is a major supplier to the U.S. government and supports the U.S. Navy’s nuclear propulsion program by designing and manufacturing nuclear reactors and related components for naval vessels. Its offerings also include nuclear fuel, reactor components, engineering and maintenance services, and technologies intended for advanced and small modular reactors.

Through its commercial and medical businesses, BWXT provides nuclear equipment and services for civilian power generation, produces medical radioisotopes and related technologies, and supports research and other specialized applications.